darunavir cobicistat - versus control - for COVID 19 all comers pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.00 [0.02, 53.89]< 10%1 study (1/-)50.0 %highnot evaluable lowcrucial-
deaths 1.00 [0.02, 53.89]< 10%1 study (1/-)50.0 %highnot evaluable lowcrucial-
clinical deterioration 2.07 [0.06, 66.79]< 10%1 study (1/-)34.3 %highnot evaluable lowimportant-
mechanical ventilation 2.07 [0.06, 66.79]< 10%1 study (1/-)34.3 %highnot evaluable lowimportant-
viral clearance 0.82 [0.36, 1.87]> 10%1 study (1/-)31.9 %highnot evaluable lowimportant-
viral clearance (time to event analysis only) 0.82 [0.36, 1.87]> 10%1 study (1/-)31.9 %highnot evaluable lowimportant-
viral clearance by day 7 0.58 [0.14, 2.48]> 10%1 study (1/-)23.3 %highnot evaluable lowimportant-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.